Subscribe To
Allyx therapeutics to present phase 1 data for lead compound alx-001 at the 16th clinical trials on alzheimer’s disease meeting
Allyx’s lead compound, ALX-001, is a small molecule with unique mechanism of action at mGluR5, to protect and preserve synapses in ...
October 19, 2023, 8:05 pm
Tiziana life sciences reveals positive pet scan results with foralumab to treat ms patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) s...
October 13, 2023, 8:34 am
Novartis leads funding round for uk alzheimer's specialist
UK-based biotech firm AstronauTx has secured £48 million ($61 million) in a significant Series A funding round, marking a step towards developing tre...
October 9, 2023, 2:16 am
Vigil neuroscience to present at jefferies inaugural biotech cns/neuro summit
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harne...
October 5, 2023, 4:01 pm
Us fda panel votes against brainstorm's als therapy
The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis ...
September 27, 2023, 6:10 pm
Biovie complements its alzheimer's clinical research program with social impact initiatives
What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is...
September 26, 2023, 3:29 pm
Annexon biosciences to participate in the 2023 cantor global healthcare conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class o...
September 19, 2023, 6:30 am
Vigil neuroscience: interesting early data, wait for phase 2
Vigil Neuroscience is developing medicines for neurodegenerative diseases by restoring microglial funct...
September 18, 2023, 2:38 pm
Zyversa therapeutics announces research published in frontiers in immunology reinforcing ic 100’s rationale for inhibiting multiple inflammasomes to control inflammation in various inflammatory diseas
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative...
September 12, 2023, 10:30 am
Vigil neuroscience to present at 2023 morgan stanley global healthcare conference
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to har...
September 8, 2023, 11:05 am
Promis neurosciences to present at the h.c. wainwright 25th annual global investment conference
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company foc...
September 6, 2023, 12:18 pm
Ac immune (aciu) surges 43% in the past 3 months: here's why
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for ...
September 5, 2023, 2:17 pm
Clene to present at upcoming september conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary...
August 30, 2023, 8:20 am
Rare neurodegenerative disease treatment market to cross us$ 119.2 billion valuation by 2033 | fact.mr report
Advances in Genetic Research and Personalized Medicine is a key driver which is helping to shape the Rare neur...
August 23, 2023, 9:00 am
Fsd pharma selected to present its phase 1 data on lucid-ms at msmilan 2023 – 9th joint ectrims-actrims meeting for october 11-13, 2023
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HU...
August 15, 2023, 7:30 am
Anavex life sciences reports publication of anavex®3-71 in clinical journal confirming anavex®3-71 clinical cardiovascular safety
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharma...
August 7, 2023, 11:30 am
Ac immune reports second quarter 2023 financial results and provides a corporate update
Lausanne, Switzerland, August 4, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for ...
August 4, 2023, 11:30 am
Anavex life sciences to announce fiscal 2023 third quarter financial results on tuesday august 8, 2023
Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (�...
August 1, 2023, 11:30 am
Why shares of amylyx pharmaceuticals were up monday
Amylyx focuses on neurodegenerative diseases. After launching its first product in September, the compa...
July 24, 2023, 12:17 pm
Annexon to report archer phase 2 trial results in geographic atrophy at asrs 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET BRISBANE, Calif., July 24, 2023 (GLOBE NEWSWIRE) — ...
July 24, 2023, 10:30 am